Ventas, Inc. VTR
Composite 42/100; the shares have moved about 26% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 18/100 — a strong mark against it.
Growth ranks 80/100 — a strong point in its favour. Income ranks 62/100 — a moderate point in its favour. Momentum ranks 61/100 — a slight point in its favour.
Balance-sheet strength ranks 18/100 — a strong mark against it. Valuation ranks 24/100 — a strong mark against it. Quality ranks 38/100 — a moderate mark against it.
What the company does Ventas (VTR) operates 1,450 healthcare properties across North America and the UK, specializing in senior housing (900+ communities), outpatient medical buildings, research centers, and healthcare facilities. Its Ventas OITM platform leverages data-driven insights to support operational efficiency and growth in the longevity economy.
Key financials VTR’s profitability metrics are weak: ROE 2%, ROA 2.2%, ROCE 3.5%, and net margins at 4.1%. Revenue growth is strong at 21.7%, but EPS declined -6.7%. Debt/Equity is 0.85 with net debt/EBITDA at 5.34 and interest coverage of 1.31, indicating elevated leverage risk.
Stock health Momentum is mixed: +38.02% over 12 months but -9.92% below the 52-week high. The Sideravia score labels quality as poor (36.6) but highlights income (61.9) and momentum (59.7). The dividend yield is 2.2% with a payout ratio of 1.5%.
Price vs fair value The stock trades at a **discount of 10.00%** to the analyst mean target of 100.64 (Valuation anchor). - Simply Wall St. notes “Ventas stock looks reasonable even with mixed value signals” (Simply Wall St.). - RBC highlights “earnings growth supported by strong senior housing trends” (MT Newswires).
Looking forward Forward P/E of 151.52 and PEG of 15.42 suggest high expectations are priced in. Weak profitability and leverage ratios remain key risks despite top-line growth and income appeal.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.